Online inquiry

IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10626MR)

This product GTTS-WQ10626MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10626MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ563MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ7228MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ6852MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ6144MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ7406MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ9837MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ865MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ12057MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MNRP1685A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW